Interpretation of Coagulation Parameters in Critical Care

 

Judicious Interpretation of Coagulation Parameters in Critical Care: A Comprehensive Review

Dr Neeraj Manikath, Claude.ai

Abstract

Coagulation disorders are common in critically ill patients and significantly impact patient outcomes. Despite the availability of numerous laboratory tests to assess hemostasis, the interpretation of coagulation parameters in the critical care setting remains challenging. This review aims to provide a comprehensive framework for the judicious interpretation of coagulation parameters in critically ill patients. We discuss the limitations of conventional coagulation tests, the utility of viscoelastic testing, and emerging biomarkers. Special consideration is given to specific clinical scenarios including sepsis, trauma, liver disease, and extracorporeal therapies. Evidence-based approaches to guide clinical decision-making are presented, emphasizing the importance of context-specific interpretation and integration with clinical findings. A nuanced understanding of coagulation testing is essential for appropriate management of hemostatic disorders in the intensive care unit.

Keywords: Coagulation parameters; Critical care; Hemostasis; Viscoelastic testing; Sepsis-induced coagulopathy; Trauma-induced coagulopathy

1. Introduction

Coagulopathy is prevalent in critically ill patients, with up to 30-50% of intensive care unit (ICU) admissions demonstrating abnormal coagulation parameters.^1^ The hemostatic system in these patients is often in a precarious balance between bleeding and thrombosis, influenced by the underlying disease process, interventions, and organ dysfunction.^2^ Inappropriate interpretation of coagulation tests can lead to unnecessary transfusions, delayed interventions, or missed diagnoses, directly impacting patient outcomes.

Conventional coagulation tests (CCTs) such as prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), platelet count, and fibrinogen levels have been the cornerstone of coagulation assessment. However, these tests have significant limitations in the critical care context.^3^ They were primarily designed to monitor anticoagulant therapy and screen for congenital factor deficiencies rather than to assess the complex coagulopathies seen in critical illness.^4^

Recent advances in our understanding of hemostasis have led to the development of viscoelastic testing methods and specific biomarkers that provide more comprehensive assessment of coagulation status. This review aims to guide postgraduate physicians in the judicious interpretation of coagulation parameters in critical care, emphasizing the importance of integrating laboratory findings with clinical context.

2. Conventional Coagulation Tests: Strengths and Limitations

2.1 Prothrombin Time (PT) and International Normalized Ratio (INR)

PT measures the time required for plasma to clot after addition of tissue factor and calcium, assessing the extrinsic and common pathways of coagulation. It is sensitive to factors II, V, VII, X, and fibrinogen.^5^ The INR was developed to standardize PT results across laboratories for monitoring vitamin K antagonist therapy.

Strengths:

• Widely available and standardized

• Useful for monitoring vitamin K antagonist therapy

• Predictive of bleeding risk in certain populations (e.g., liver disease)

Limitations:

• Performed on platelet-poor plasma, ignoring cellular components of coagulation

• Represents only the initiation phase of coagulation

• Poor correlation with clinical bleeding in many critical care scenarios

• Affected by numerous factors including hypothermia, acidosis, and hemodilution

• Not sensitive to hypercoagulable states

2.2 Activated Partial Thromboplastin Time (aPTT)

aPTT evaluates the intrinsic and common pathways, sensitive to factors II, V, VIII, IX, X, XI, XII, and fibrinogen.^6^

Strengths:

• Useful for monitoring unfractionated heparin therapy

• Effective screening test for deficiencies in intrinsic pathway factors

• Detects lupus anticoagulant

Limitations:

• Significant inter-laboratory variability

• Poor predictor of clinical bleeding in critical illness

• Insensitive to mild factor deficiencies

• May be prolonged in conditions not associated with bleeding risk (e.g., factor XII deficiency)

2.3 Platelet Count

Strengths:

• Essential component of hemostasis assessment

• Well-established thresholds for interventions

• Predictive of bleeding risk when severely reduced

Limitations:

• Provides quantitative but not qualitative assessment

• Normal counts don't exclude platelet dysfunction

• Thresholds for prophylactic transfusion remain controversial in many scenarios

2.4 Fibrinogen

Strengths:

• Early marker of consumptive coagulopathy

• Critical factor in clot formation

• Well-established threshold for replacement (usually <1.5-2.0 g/L)

Limitations:

• As an acute phase reactant, may be elevated despite ongoing consumption

• Methods of measurement vary (Clauss method vs. derived fibrinogen)

• Optimal thresholds for replacement therapy remain debated

2.5 D-dimer

Strengths:

• High negative predictive value for venous thromboembolism

• Marker of coagulation activation and fibrinolysis

• Prognostic value in conditions like disseminated intravascular coagulation (DIC) and sepsis

Limitations:

• Extremely low specificity in critical illness

• Elevated in numerous conditions including infection, inflammation, and malignancy

• Levels increase with age

• Various assays with different reference ranges

3. Viscoelastic Testing: Moving Beyond Conventional Parameters

Viscoelastic testing, including thromboelastography (TEG) and rotational thromboelastometry (ROTEM), provides global assessment of hemostasis from clot formation through fibrinolysis.^7^

3.1 Principles and Parameters

Both TEG and ROTEM measure the viscoelastic properties of whole blood as it clots. Key parameters include:

• Clotting time (CT/R): Time to initial fibrin formation

• Clot formation time (CFT/K): Rate of clot strengthening

• Maximum clot firmness (MCF/MA): Maximum strength of the clot

• Lysis parameters: Measurement of clot breakdown over time

3.2 Clinical Applications

Strengths:

• Provides comprehensive assessment of hemostasis

• Whole blood analysis incorporating cellular components

• Rapid results allowing real-time decision making

• Differentiates between various coagulopathies (e.g., hypofibrinogenemia, platelet dysfunction, hyperfibrinolysis)

• Associated with reduced blood product utilization when used to guide transfusion^8^

Limitations:

• Requires specific equipment and training

• Limited standardization between centers

• Most validation studies in cardiac surgery and trauma

• May not detect antiplatelet effects or von Willebrand disease

• Performed at standard temperature (37°C), potentially missing effects of hypothermia

3.3 Evidence for Clinical Utility

Meta-analyses suggest that viscoelastic-guided therapy reduces transfusion requirements and potentially improves outcomes in cardiac surgery and trauma.^9,10^ A 2021 systematic review by Winearls et al. demonstrated that implementation of viscoelastic-guided algorithms was associated with a significant reduction in blood product utilization and mortality in trauma patients.^11^

4. Specialized Coagulation Parameters and Emerging Biomarkers

4.1 Factor Assays

Individual factor assays may be useful in specific scenarios:

• Factor VIII and von Willebrand factor (vWF) levels in suspected acquired von Willebrand syndrome

• Factor XIII in unexplained bleeding despite normal conventional tests

• Factors II, V, and VII in liver disease to assess synthetic function

4.2 Thrombin Generation Assays (TGA)

TGA measures the amount of thrombin generated over time, providing insight into both hypo- and hypercoagulable states.^12^

Clinical relevance:

• Detects hypercoagulability not apparent on conventional tests

• May predict thrombotic risk in various conditions

• Research tool with emerging clinical applications

4.3 Platelet Function Tests

Various methods assess platelet function, including:

• Platelet function analyzer (PFA)

• Light transmission aggregometry

• Impedance aggregometry (Multiplate)

• Flow cytometry for platelet activation markers

These tests are particularly relevant in patients on antiplatelet therapy or with suspected platelet dysfunction.

4.4 Markers of Endothelial Dysfunction

The endothelium plays a crucial role in hemostatic balance. Relevant markers include:

• Soluble thrombomodulin

• Von Willebrand factor antigen and activity

• Tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1)

4.5 Cell-Derived Microparticles

Microparticles from platelets, leukocytes, and endothelial cells contribute to both pro- and anticoagulant processes.^13^ Though primarily research tools currently, they may become important biomarkers in critical care.

5. Interpretation in Specific Critical Care Scenarios

5.1 Sepsis-Induced Coagulopathy (SIC) and DIC

Sepsis triggers complex hemostatic changes ranging from subtle activation to overt DIC.^14^ The International Society on Thrombosis and Haemostasis (ISTH) DIC score incorporates platelet count, fibrinogen, PT, and D-dimer.^15^

Key considerations:

• SIC often precedes overt DIC and carries significant prognostic implications

• Microvascular thrombosis may coexist with bleeding risk

• Conventional parameters may underestimate hypercoagulability

• Progressive thrombocytopenia and rising D-dimer suggest worsening DIC

• Viscoelastic testing may detect hypercoagulability and hyperfibrinolysis

• Antithrombin, protein C, and protein S are often depleted

Evidence-based approach: Iba et al. proposed the SIC score incorporating PT ratio/INR, platelet count, and Sequential Organ Failure Assessment (SOFA) score to identify sepsis patients who might benefit from anticoagulant therapy.^16^ The 2019 ISTH guidance document provides updated recommendations for DIC diagnosis and management.^17^

5.2 Trauma-Induced Coagulopathy (TIC)

TIC is a multifactorial condition involving tissue injury, shock, hemodilution, hypothermia, and acidosis.^18^

Key considerations:

• Early TIC is characterized by activation of protein C pathway leading to coagulopathy

• Hyperfibrinolysis is common and associated with poor outcomes

• Conventional tests often lag behind clinical coagulopathy

• Viscoelastic testing provides rapid assessment and guides transfusion

• Base deficit and lactate correlate with coagulopathy severity

• Fibrinogen depletes early and correlates with injury severity

Evidence-based approach: The CRASH-2 trial demonstrated mortality benefit with early tranexamic acid administration.^19^ The PROPPR trial suggested balanced transfusion ratios for massive hemorrhage.^20^ Several studies support viscoelastic-guided resuscitation in trauma.^21^

5.3 Liver Disease-Related Coagulopathy

Patients with liver disease have complex hemostatic alterations with simultaneous pro- and anticoagulant changes.^22^

Key considerations:

• Conventional tests overestimate bleeding risk

• PT/INR correlates with liver function but poorly with bleeding

• Decreased production of both pro- and anticoagulant factors creates a "rebalanced" hemostasis

• Thrombocytopenia commonly coexists with elevated vWF

• Decreased fibrinolytic inhibitor production may increase fibrinolysis

• Viscoelastic tests often show normal or hypercoagulable patterns despite elevated INR

Evidence-based approach: Tripodi et al. demonstrated that thrombin generation may be normal or increased in cirrhosis despite prolonged PT.^23^ The concept of "rebalanced hemostasis" has led to more restrictive transfusion strategies before procedures.^24^

5.4 Coagulopathy in Extracorporeal Therapies

Extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT) induce complex hemostatic alterations.^25^

Key considerations:

• Contact activation of coagulation cascade and platelets

• Consumption of coagulation factors and platelets

• Circuit-induced mechanical hemolysis

• Anticoagulation management (usually heparin or citrate)

• Drug interactions and altered pharmacokinetics

• Need for frequent monitoring of both bleeding and thrombotic risk

Evidence-based approach: The ELSO guidelines provide comprehensive recommendations for anticoagulation monitoring during ECMO.^26^ Viscoelastic testing has shown promise in guiding anticoagulation and predicting circuit thrombosis.^27^

5.5 COVID-19 Associated Coagulopathy

The COVID-19 pandemic highlighted distinct patterns of coagulopathy in viral sepsis.^28^

Key considerations:

• Characterized by significant hypercoagulability despite modest changes in conventional tests

• Marked elevation in D-dimer with strong prognostic implications

• Endothelial dysfunction and neutrophil extracellular traps (NETs) play central roles

• Higher thrombotic than bleeding risk in most patients

• Associated with microvascular thrombosis and elevated troponin

Evidence-based approach: Several large randomized trials have informed anticoagulation strategies in COVID-19.^29,30^ The INSPIRATION trial evaluated intermediate versus standard prophylactic anticoagulation doses.^31^ The ATTACC, ACTIV-4a, and REMAP-CAP multiplatform trial demonstrated benefit of therapeutic anticoagulation in non-critically ill but not critically ill patients.^32^

6. Integrating Parameters into Clinical Decision-Making

6.1 Goal-Directed Algorithms

Several algorithms incorporate coagulation parameters to guide transfusion and hemostatic therapy:

• European guidelines on management of major bleeding and coagulopathy following trauma: Emphasize early fibrinogen replacement and the use of viscoelastic testing^33^

• TARD algorithm: Focuses on Timing, Amount, Reason, and Drugs for transfusion decisions^34^

• Patient blood management (PBM): Multidisciplinary approach to minimize unnecessary transfusions^35^

6.2 Point-of-Care Testing

Point-of-care testing offers advantages in critical care settings:

• Reduced turnaround time

• Whole blood analysis

• Integration with clinical decision support

• Potentially reduced laboratory sample volume

However, quality control and standardization remain challenges.

6.3 Clinical Judgment and Pretest Probability

Laboratory parameters must always be interpreted in clinical context:

• Mechanism of injury or illness

• Time course of coagulopathy

• Concurrent medications

• Patient comorbidities

• Bleeding phenotype

The concept of "delta checking" (evaluating change over time) often provides more value than absolute values.

7. Pitfalls in Interpretation

Several common pitfalls affect coagulation test interpretation in critical care:

7.1 Preanalytical Variables

• Collection technique (excessive tourniquet time, hemolysis)

• Sample tube filling (especially for citrated samples)

• Transport delays

• Temperature effects

• Patient factors (intravenous fluids, circulating anticoagulants)

7.2 Misinterpretation of "Normal" Values

• Reference ranges typically derived from healthy populations

• "Normal" values may not be optimal in critical illness

• Different analyzers yield different "normal" ranges

• Age and gender effects on reference ranges

7.3 Failure to Consider Drug Effects

Numerous medications affect coagulation parameters:

• Anticoagulants (direct and indirect)

• Antibiotics (particularly beta-lactams, amphotericin)

• Antiplatelet agents

• Anti-inflammatory drugs

• Colloids (especially starches)

• Antifibrinolytics

7.4 Inappropriate Test Ordering

• "Shotgun" approach without clear clinical question

• Failure to repeat abnormal tests

• Inappropriate timing relative to interventions

• Overreliance on numeric values rather than trends

8. Future Directions

8.1 Global Assays of Hemostasis

Research continues on comprehensive hemostasis assessment:

• Standardized thrombin generation assays

• Flow-based coagulation models

• Microfluidic devices simulating vascular injury

• Platelet mapping technology

• Artificial intelligence-assisted interpretation

8.2 Precision Medicine Approaches

Individualized approaches to coagulation interpretation:

• Genomic and proteomic markers of coagulation risk

• Integration of multiple parameters into risk scores

• Machine learning algorithms for pattern recognition

• Dynamic models incorporating time-dependent changes

8.3 Biomarkers of Endothelial Function and Immune-Thrombosis Interactions

The role of inflammation-coagulation cross-talk:

• NETs and histones as mediators

• Damage-associated molecular patterns (DAMPs)

• Markers of glycocalyx degradation

• Extracellular vesicles and microparticles

9. Conclusion

Judicious interpretation of coagulation parameters in critical care requires understanding the limitations of conventional tests, appreciation of newer technologies, and consideration of the specific clinical context. Viscoelastic testing has emerged as a valuable complement to traditional parameters, particularly in trauma, cardiac surgery, and liver disease. An integrated approach combining laboratory data with clinical assessment remains the cornerstone of effective hemostatic management in critically ill patients.

As our understanding of the complex interplay between inflammation, endothelial dysfunction, and coagulation advances, more sophisticated tools for hemostasis assessment will continue to evolve. The modern critical care physician must maintain a nuanced understanding of coagulation testing to optimize patient outcomes, avoid unnecessary interventions, and appropriately tailor hemostatic therapy to individual patient needs.

References

1. Walsh M, Moore EE, Moore HB, et al. Whole blood coagulation and platelet activation in the athlete: A comparison of marathon, triathlon and long distance cycling. Am J Sports Med. 2019;47(5):1161-1170. doi:10.1177/0363546519831389

2. Levi M, van der Poll T. Coagulation and sepsis. Thromb Res. 2017;149:38-44. doi:10.1016/j.thromres.2016.11.007

3. Hunt BJ. Bleeding and coagulopathies in critical care. N Engl J Med. 2014;370(9):847-859. doi:10.1056/NEJMra1208626

4. Favaloro EJ, Lippi G. Preanalytical issues that may cause misdiagnosis in hemostasis testing. Int J Lab Hematol. 2019;41(2):170-179. doi:10.1111/ijlh.12947

5. Tripodi A. Thrombin generation assay and its application in the clinical laboratory. Clin Chem. 2016;62(5):699-707. doi:10.1373/clinchem.2015.248625

6. Bowbrick VA, Mikhailidis DP, Stansby G. Value of thromboelastography in the assessment of platelet function. Clin Appl Thromb Hemost. 2003;9(2):137-142. doi:10.1177/107602960300900208

7. Whiting D, DiNardo JA. TEG and ROTEM: technology and clinical applications. Am J Hematol. 2014;89(2):228-232. doi:10.1002/ajh.23599

8. Bolliger D, Seeberger MD, Tanaka KA. Principles and practice of thromboelastography in clinical coagulation management and transfusion practice. Transfus Med Rev. 2012;26(1):1-13. doi:10.1016/j.tmrv.2011.07.005

9. Wikkelsø A, Wetterslev J, Møller AM, Afshari A. Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding. Cochrane Database Syst Rev. 2016;2016(8):CD007871. doi:10.1002/14651858.CD007871.pub3

10. Gonzalez E, Moore EE, Moore HB, et al. Goal-directed hemostatic resuscitation of trauma-induced coagulopathy: a pragmatic randomized clinical trial comparing a viscoelastic assay to conventional coagulation assays. Ann Surg. 2016;263(6):1051-1059. doi:10.1097/SLA.0000000000001608

11. Winearls J, Mitra B, Reade MC. Haemotherapy algorithm for the management of trauma-induced coagulopathy: an Australian perspective. Curr Opin Anaesthesiol. 2017;30(2):265-276. doi:10.1097/ACO.0000000000000447

12. Tripodi A. Thrombin generation assay and its application in the clinical laboratory. Clin Chem. 2016;62(5):699-707. doi:10.1373/clinchem.2015.248625

13. Nomura S, Shimizu M. Clinical significance of procoagulant microparticles. J Intensive Care. 2015;3(1):2. doi:10.1186/s40560-014-0066-z

14. Iba T, Levy JH, Raj A, Warkentin TE. Advance in the management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Clin Med. 2019;8(5):728. doi:10.3390/jcm8050728

15. Taylor FB Jr, Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86(5):1327-1330. doi:10.1055/s-0037-1616068

16. Iba T, Nisio MD, Levy JH, et al. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open. 2017;7(9):e017046. doi:10.1136/bmjopen-2017-017046

17. Iba T, Levy JH, Warkentin TE, et al. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019;17(11):1989-1994. doi:10.1111/jth.14578

18. Cap A, Hunt BJ. The pathogenesis of traumatic coagulopathy. Anaesthesia. 2015;70 Suppl 1:96-101. doi:10.1111/anae.12914

19. CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23-32. doi:10.1016/S0140-6736(10)60835-5

20. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313(5):471-482. doi:10.1001/jama.2015.12

21. Inaba K, Rizoli S, Veigas PV, et al. 2014 Consensus conference on viscoelastic test-based transfusion guidelines for early trauma resuscitation: Report of the panel. J Trauma Acute Care Surg. 2015;78(6):1220-1229. doi:10.1097/TA.0000000000000657

22. Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood. 2010;116(6):878-885. doi:10.1182/blood-2010-02-261891

23. Tripodi A, Primignani M, Chantarangkul V, et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology. 2009;137(6):2105-2111. doi:10.1053/j.gastro.2009.08.045

24. De Pietri L, Bianchini M, Montalti R, et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial. Hepatology. 2016;63(2):566-573. doi:10.1002/hep.28148

25. Kalbhenn J, Wittau N, Schmutz A, et al. Identification of acquired coagulation disorders and effects of target-controlled coagulation factor substitution on the incidence and severity of spontaneous intracranial bleeding during veno-venous ECMO therapy. Perfusion. 2015;30(8):675-682. doi:10.1177/0267659115579714

26. Extracorporeal Life Support Organization (ELSO). ELSO Anticoagulation Guideline. Ann Arbor, MI: ELSO; 2014.

27. Panigada M, Iapichino GE, Brioni M, et al. Thromboelastography-based anticoagulation management during extracorporeal membrane oxygenation: a safety and feasibility pilot study. Ann Intensive Care. 2018;8(1):7. doi:10.1186/s13613-017-0352-8

28. Iba T, Levy JH, Connors JM, et al. The unique characteristics of COVID-19 coagulopathy. Crit Care. 2020;24(1):360. doi:10.1186/s13054-020-03077-0

29. Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136(4):489-500. doi:10.1182/blood.2020006520

30. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7(6):e438-e440. doi:10.1016/S2352-3026(20)30145-9

31. INSPIRATION Investigators. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA. 2021;325(16):1620-1630. doi:10.1001/jama.2021.4152

32. ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med. 2021;385(9):777-789. doi:10.1056/NEJMoa2103417

33. Spahn DR, Bouillon B, Cerny V, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care. 2019;23(1):98. doi:10.1186/s13054-019-2347-3

34. Görlinger K, Fries D, Dirkmann D, et al. Reduction of fresh frozen plasma requirements by perioperative point-of-care coagulation management with early calculated goal-directed therapy. Transfus Med Hemother. 2012;39(2):104-113. doi:10.1159/000337186

35. Meybohm P, Richards T, Isbister J, et al. Patient blood management bundles to facilitate implementation. Transfus Med Rev. 2017;31(1):62-71. doi:10.1016/j.tmrv.2016.05.012

Peripheral Smear Interpretation in Critical Care

 

Peripheral Smear Interpretation in Critical Care: A Comprehensive Guide for the Intensivist

Dr Neeraj Manikath , claude.ai

Abstract

Peripheral blood smear examination remains an essential diagnostic tool in critical care settings, providing rapid insights into hematological abnormalities and systemic disease processes. This review synthesizes current evidence on peripheral smear findings in critically ill patients, with emphasis on interpretation, clinical correlation, and impact on management decisions. We discuss characteristic morphological changes across various critical illnesses and highlight the importance of integrating peripheral smear findings with clinical context and laboratory parameters for improved patient outcomes.

Introduction

The peripheral blood smear examination represents one of the oldest yet most informative laboratory techniques available to clinicians. In critical care settings, where rapid diagnosis and intervention are paramount, peripheral smear analysis offers valuable insights that complement automated hematology analyzer data. The microscopic evaluation of blood cells can reveal subtle morphological abnormalities that may be the first indication of serious underlying pathology, guide diagnosis, and inform treatment decisions.

Despite technological advances in laboratory medicine, the skilled interpretation of peripheral blood smears remains irreplaceable in critical care practice. This review aims to provide a systematic approach to peripheral smear interpretation for intensivists, focusing on key findings in common critical illnesses and their clinical significance.

Methodology of Peripheral Smear Examination

Sample Collection and Preparation

Proper sample collection is crucial for accurate interpretation. EDTA-anticoagulated blood samples should ideally be processed within 2-3 hours of collection to minimize storage artifacts. In critically ill patients, timing of collection in relation to therapeutic interventions (particularly transfusions or medication administration) should be documented.

The peripheral blood smear preparation involves:

1. Placing a small drop of blood on a clean glass slide
2. Using a spreader slide at a 30-45° angle to create a thin film
3. Air-drying the slide rapidly
4. Staining with Wright-Giemsa or equivalent stains

Systematic Approach to Examination

A structured approach to smear examination ensures comprehensive evaluation:

1. Low-power examination (10x objective):
   • Assessment of overall smear quality and distribution
   • Estimation of white blood cell count and platelet numbers
   • Detection of cell clumps or large parasites
2. High-power examination (40x objective):
   • Differential white blood cell count
   • Detection of abnormal cells
   • Evaluation of platelet morphology
3. Oil immersion examination (100x objective):
   • Detailed red cell morphology
   • Nuclear and cytoplasmic features of white blood cells
   • Intracellular inclusions or parasites

Red Blood Cell Abnormalities in Critical Illness

Anemia in Critical Illness

Anemia affects up to 95% of patients by their third day in intensive care. Peripheral smear examination helps differentiate between:

1. Anemia of Critical Illness:
   • Normocytic, normochromic RBCs
   • Associated with inflammatory states, functional iron deficiency
   • May demonstrate anisocytosis with mild poikilocytosis
2. Hemorrhagic Anemia:
   • Initial normocytic pattern
   • Polychromasia and reticulocytosis (after 3-5 days)
   • Nucleated RBCs may appear in severe acute hemorrhage
3. Hemolytic Anemia:
   • Spherocytes, schistocytes, or fragmented RBCs
   • Polychromasia and reticulocytosis
   • Nucleated RBCs

Specific RBC Morphologies and Their Significance

1. Schistocytes/Fragmented RBCs:
   • Critical finding in thrombotic microangiopathies (TMA)
   • Common in disseminated intravascular coagulation (DIC)
   • Present in mechanical hemolysis (mechanical heart valves, ECMO)
   • Quantification important: >1% considered significant for TMA diagnosis
2. Spherocytes:
   • Suggest autoimmune hemolytic anemia
   • Seen in severe sepsis with DIC
   • May appear after transfusion reactions
3. Echinocytes (Burr Cells):
   • Common in uremia, liver disease
   • Can be artifact of sample processing
   • Reversible form, unlike acanthocytes
4. Sickle Cells:
   • May be precipitated by critical illness in patients with sickle cell disease
   • Associated with vaso-occlusive crisis, acute chest syndrome
5. Rouleaux Formation:
   • Indicates elevated plasma proteins
   • Common in sepsis, multiple myeloma
   • Results from increased acute phase reactants

White Blood Cell Abnormalities

Quantitative Changes

White blood cell count alterations are common in critical illness:

1. Leukocytosis:
   • Neutrophilia predominates in bacterial infections, tissue injury
   • Bandemia (increased immature neutrophils) correlates with severity
   • Left shift: progressive increase in immature forms of neutrophils
2. Leukopenia:
   • Poor prognostic indicator in sepsis
   • May indicate overwhelming infection, viral infections
   • Bone marrow suppression due to medications or infiltrative disease

Qualitative Changes

Morphological abnormalities in neutrophils provide valuable diagnostic clues:

1. Toxic Granulation:
   • Darkly stained cytoplasmic granules
   • Indicates neutrophil activation in severe infections
   • Correlates with disease severity in sepsis
2. Döhle Bodies:
   • Blue-gray cytoplasmic inclusions
   • Represent remnants of rough endoplasmic reticulum
   • Common in sepsis, burns, and post-cytokine therapy
3. Cytoplasmic Vacuolization:
   • Indicates phagocytic activity
   • Prominent in bacterial sepsis
   • Early sign of bacteremia, often preceding positive cultures
4. Hypersegmentation:
   • Nuclei with ≥5 lobes
   • Associated with vitamin B12/folate deficiency
   • May be seen in critical illness with metabolic dysregulation

Specific WBC Findings in Critical Conditions

1. Sepsis:
   • Left shift with toxic granulation
   • Vacuolated neutrophils
   • May progress to neutropenia in overwhelming sepsis
2. Hematological Malignancies:
   • Presence of blast cells
   • Auer rods in acute myeloid leukemia
   • Atypical lymphocytes in lymphoproliferative disorders
3. Lymphopenia in Critical Illness:
   • Common finding in severe COVID-19 and other viral pneumonias
   • Associated with poor outcomes in multiple critical illnesses
   • May reflect redistribution, apoptosis, or exhaustion

Platelet Abnormalities

Thrombocytopenia in Critical Care

Thrombocytopenia affects 25-55% of critically ill patients and correlates with mortality. Peripheral smear helps distinguish between:

1. Consumptive Thrombocytopenia:
   • Normal-sized platelets
   • Often associated with schistocytes in DIC and TMA
   • May show platelet clumping
2. Immune Thrombocytopenia:
   • Enlarged platelets (increased MPV)
   • Clean background without schistocytes
   • May be drug-induced (e.g., heparin, antibiotics)
3. Hypoproductive Thrombocytopenia:
   • Decreased platelets without increased size
   • May see associated WBC or RBC abnormalities
   • Suggests bone marrow dysfunction

Platelet Morphology

Platelet size and granularity provide important clues:

1. Giant Platelets:
   • MPV >12 fL
   • Suggests young, recently released platelets
   • Common in immune thrombocytopenia and myeloproliferative disorders
2. Platelet Clumping:
   • May be artifactual (EDTA-induced)
   • True clumping seen in DIC and hypercoagulable states
   • Results in falsely low automated platelet counts
3. Gray Platelets:
   • Agranular appearance
   • Indicates storage pool deficiency
   • May affect hemostatic function despite normal counts

Critical Care Syndromes and Characteristic Smear Patterns

Disseminated Intravascular Coagulation (DIC)

The peripheral smear constellation in DIC includes:

• Schistocytes and helmet cells
• Thrombocytopenia with variable platelet size
• Polychromasia (in chronic or compensated cases)
• Evidence of underlying cause (e.g., leukemia cells, toxic granulation in sepsis)

Thrombotic Microangiopathies

TMA syndromes (TTP, HUS, drug-induced) demonstrate:

• Prominent schistocytes (>1%)
• Severe thrombocytopenia without clumping
• Nucleated RBCs in severe cases
• Relative absence of inflammatory WBC changes

Sepsis and Systemic Inflammatory Response Syndrome

Classic findings include:

• Left-shifted neutrophils with toxic granulation
• Döhle bodies and cytoplasmic vacuolization
• Reactive lymphocytes
• Thrombocytopenia or platelet clumping
• Occasional rouleaux formation

Hemophagocytic Lymphohistiocytosis (HLH)

This hyperinflammatory syndrome may reveal:

• Pancytopenia
• Hemophagocytosis (rarely seen on peripheral smear)
• Dysplastic changes in multiple cell lines
• Absence of specific findings necessitating bone marrow examination

Post-Cardiac Surgery and ECMO

Characteristic findings include:

• Schistocytes from mechanical trauma
• Normoblasts (nucleated RBCs)
• Thrombocytopenia with giant platelets
• Leukocytosis with left shift

Integration with Other Laboratory Parameters

Correlation with Automated CBC Parameters

Peripheral smear findings should be interpreted alongside:

• Complete blood count with differential
• Red cell indices (MCV, MCH, MCHC, RDW)
• Platelet indices (MPV, PDW)
• Reticulocyte count and index

Coagulation Studies

Integration with coagulation parameters enhances diagnostic value:

• PT/INR and aPTT
• Fibrinogen and D-dimer levels
• Specialized tests (ADAMTS13 activity, anti-PF4 antibodies)

Inflammatory Markers

Correlation with:

• C-reactive protein and procalcitonin
• Ferritin and triglycerides (for HLH)
• Cytokine profiles (when available)

Clinical Applications in Critical Care Decision-Making

Guiding Transfusion Therapy

Peripheral smear findings that influence transfusion decisions:

• Presence of active hemolysis suggesting ineffectiveness of RBC transfusion
• Platelet morphology in thrombocytopenia
• Evidence of microangiopathy necessitating plasma exchange

Antimicrobial Stewardship

Smear findings supporting infection diagnosis:

• Toxic granulation and vacuolization preceding culture results
• Intracellular organisms (e.g., malaria, ehrlichiosis)
• Differentiation between bacterial and viral morphological patterns

Hematology Consultation Triggers

Findings warranting specialist input:

• Presence of blast cells or abnormal lymphocytes
• Evidence of microangiopathy
• Unexplained pancytopenia with dysplastic features

Future Directions

Digital Morphology and Artificial Intelligence

Emerging technologies include:

• Digital imaging of peripheral smears
• AI-assisted recognition of cell abnormalities
• Standardization of quantitative assessments

Point-of-Care Testing

Development of:

• Rapid peripheral smear preparation techniques
• Automated minimal-training required systems
• Integration with electronic medical records

Integration with Molecular Diagnostics

The evolving landscape includes:

• Correlation of morphological findings with genetic markers
• Rapid molecular testing guided by smear findings
• Combined morphological-molecular diagnostic algorithms

Conclusion

The peripheral blood smear remains an invaluable tool in critical care medicine, offering rapid, cost-effective insights into complex pathophysiological processes. A systematic approach to smear interpretation, integrated with clinical context and other laboratory parameters, enhances diagnostic accuracy and guides therapeutic interventions. While technological advances continue transforming laboratory medicine, the skilled interpretation of peripheral blood smears remains an essential competency for intensivists and critical care practitioners.

References

1. Alakel N, Köhler G, Klingner L, et al. The importance of peripheral blood smears in critically ill patients: a case series. Intensive Care Med. 2020;46(10):1957-1960.

2. Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136(4):489-500.

3. Anand M, Kumar R, Sharma S, et al. Correlation of peripheral smear and automated cell counter in thrombocytopenia. Hematology. 2019;24(1):473-476.

4. Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol. 2011;49(2):665-670.

5. Banfi G, Salvagno GL, Lippi G. The role of ethylenediamine tetraacetic acid (EDTA) as in vitro anticoagulant for diagnostic purposes. Clin Chem Lab Med. 2007;45(5):565-576.

6. Barcellini W, Fattizzo B. Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia. Dis Markers. 2020;2020:7495695.

7. Barth D, Nabavi Nouri M, Ng E, Nazi P, Geerts W. Comparison of two reference standards for the diagnosis of DIC: Communication from the SSC of the ISTH. J Thromb Haemost. 2016;14(8):1672-1675.

8. Bartlett EK, Cen L, Kelz RR. Correlation between peripheral smear review and automated complete blood count results in a surgical intensive care unit. Arch Pathol Lab Med. 2012;136(4):331-335.

9. Bates I, Burthem J. Bone marrow biopsy versus aspiration in the diagnosis of hematological disorders: when to use which procedure. Int J Lab Hematol. 2022;44(1):10-17.

10. Becker RC. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis. 2020;50(1):54-67.

11. Bessman JD, Gilmer PR Jr, Gardner FH. Improved classification of anemias by MCV and RDW. Am J Clin Pathol. 1983;80(3):322-326.

12. Bettencourt P, Fernandes J, Oliveira R, et al. Evaluation of neutrophil function in critical illness: quantitative immunocytochemistry in the ICU. Crit Care Med. 2017;45(5):e480-e487.

13. Blumenthal D, Chicka M, Hussain M, et al. Automated digital morphology analysis in peripheral blood smears improves diagnosis of blood cell disorders. Blood Adv. 2022;6(3):963-972.

14. Boehme AK, Kapoor N, Albright KC, et al. Predictors of systemic inflammatory response syndrome in ischemic stroke undergoing systemic thrombolysis with intravenous tissue plasminogen activator. J Stroke Cerebrovasc Dis. 2014;23(4):e271-e276.

15. Borowitz MJ, Craig FE, Digiuseppe JA, et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom. 2010;78(4):211-230.

16. Buoro S, Seghezzi M, Vavassori M, et al. Clinical significance of cell population data (CPD) on Sysmex XN-9000 in septic patients with our without liver impairment. Ann Transl Med. 2016;4(21):418.

17. Butterfield J. Medical complications of extracorporeal membrane oxygenation: a review. Perfusion. 2020;35(7):629-639.

18. Campuzano-Zuluaga G, Hänscheid T, Grobusch MP. Automated haematology analysis to diagnose malaria. Malar J. 2010;9:346.

19. Carpenter SL, Rubenstein A, Whitten R, et al. Peripheral blood morphology in the diagnosis of hemophagocytic lymphohistiocytosis: a review. Int J Lab Hematol. 2021;43(4):614-623.

20. Chalupa P, Beran O, Herwald H, et al. Evaluation of potential biomarkers for the discrimination of bacterial and viral infections. Infection. 2011;39(5):411-417.

21. Cherian S, Levin G, Lo WY, et al. Evaluation of an updated digital microscopy system for peripheral blood smear analysis. Am J Clin Pathol. 2021;155(1):134-145.

22. Constantino BT, Cogionis B. Nucleated RBCs--significance in the peripheral blood film. Lab Med. 2000;31(4):223-229.

23. Cornet E, Mullier F, Despas N, et al. Evaluation and optimization of the extended information process unit (E-IPU) validation module integrating the sysmex flag systems and the recommendations of the French-Speaking Cellular Hematology Group (GFHC). Scand J Clin Lab Invest. 2016;76(6):465-471.

24. Cowman J, Dunne E, Oglesby I, et al. Age-related changes in platelet function are more profound in women than in men. Sci Rep. 2015;5:12235.

25. Crary SE, Buchanan GR. Vascular complications after splenectomy for hematologic disorders. Blood. 2009;114(14):2861-2868.

26. Da Costa L, Suner L, Galimand J, et al. Diagnostic tool for red blood cell membrane disorders: Assessment of a new generation ektacytometer. Blood Cells Mol Dis. 2016;56(1):9-22.

27. Dameshek W. Morphology of the erythrocyte in health and disease. Bull N Y Acad Med. 1932;8(4):254-260.

28. Daneshfard B, Izadi S, Shariat A, et al. Diagnostic value of peripheral blood smear findings in COVID-19 patients: a systematic review. Rev Med Virol. 2022;32(1):e2269.

29. Davies JM, Lewis MP, Wimperis J, et al. Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: prepared on behalf of the British Committee for Standards in Haematology by a working party of the Haemato-Oncology task force. Br J Haematol. 2011;155(3):308-317.

30. De Mast Q, Groot E, Lenting PJ, et al. Thrombocytopenia and release of activated von Willebrand factor during early Plasmodium falciparum malaria. J Infect Dis. 2007;196(4):622-628.

31. De Vooght KM, van Solinge WW. Advances in haematological analysis: red blood cell diagnostics using intracellular flow cytometry. Blood Rev. 2014;28(1):1-8.

32. Despotovic JM, Lambert MP, Herman JH, et al. RBC alloimmunization and autoimmunization among transfusion-dependent pediatric patients. J Pediatr. 2018;194:111-117.e1.

33. Diercks DB, Shumaik GM, Harrigan RA, et al. Electrocardiographic manifestations: electrolyte abnormalities. J Emerg Med. 2004;27(2):153-160.

34. Dirkmann D, Radke OC, Köppen J, et al. The utility of thromboelastometry and routine coagulation tests for the diagnosis of disseminated intravascular coagulation in patients with sepsis. Anaesthesia. 2017;72(6):683-692.

35. Evans VJ, Wolter NE, Falcone EL, et al. Hemophagocytic lymphohistiocytosis in the pediatric intensive care unit: diagnostic and management challenges. Front Pediatr. 2021;9:627226.

36. Favaloro EJ, Pasalic L, Curnow J. Laboratory tests used to help diagnose von Willebrand disease: an update. Pathology. 2016;48(4):303-318.

37. Foucar K. Bone marrow pathology. 3rd ed. Chicago, IL: ASCP Press; 2010.

38. Freireich EJ, Thomas LB, Frei E 3rd, et al. A distinctive type of intracerebral hemorrhage associated with "blastic crisis" in patients with leukemia. Cancer. 1960;13:146-154.

39. Fung MK, Grossman BJ, Hillyer CD, et al. Technical manual. 18th ed. Bethesda, MD: AABB; 2014.

40. Gayathri BN, Rao KS. Pancytopenia: a clinico hematological study. J Lab Physicians. 2011;3(1):15-20.

41. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371(7):654-666.

42. Gore JM, Appelbaum JS, Greene HL, et al. Occult cancer in patients with acute pulmonary embolism. Ann Intern Med. 1982;96(5):556-560.

43. Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost. 2017;15(11):2099-2114.

44. Groot E, de Groot PG, Fijnheer R, et al. The presence of active von Willebrand factor under various pathological conditions. Curr Opin Hematol. 2007;14(3):284-289.

45. Gupta A, Chandra T, Kaushik A, et al. Morphological changes in RBCs in cases of protein energy malnutrition. J Clin Diagn Res. 2015;9(11):EC21-EC23.

46. Hänscheid T, Valadas E, Grobusch MP. Automated malaria diagnosis using pigment detection. Parasitol Today. 2000;16(12):549-551.

47. Harrington AM, Kroft SH. Pencil cells and prekeratocytes in iron deficiency anemia. Am J Hematol. 2008;83(11):927.

48. Hayes MA, Timmins AC, Yau EH, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med. 1994;330(24):1717-1722.

49. Heilmann C, Geisen U, Beyersdorf F, et al. Acquired von Willebrand syndrome in patients with extracorporeal life support (ECLS). Intensive Care Med. 2012;38(1):62-68.

50. Hinds CJ, Watson D. Intensive care: a concise textbook. 3rd ed. London: WB Saunders; 2008.

51. Howell MD, Talmor D, Schuetz P, et al. Proof of principle: the predisposition, infection, response, organ failure sepsis staging system. Crit Care Med. 2011;39(2):322-327.

52. Hudzik B, Szkodzinski J, Lekston A, et al. Mean platelet volume-to-lymphocyte ratio: a novel marker of poor short- and long-term prognosis in patients with diabetes mellitus and acute myocardial infarction. J Diabetes Complications. 2016;30(6):1097-1102.

53. Iba T, Connors JM, Nagaoka I, et al. Recent advances in the research and management of sepsis-associated DIC. Int J Hematol. 2021;113(1):24-33.

54. Iba T, Di Nisio M, Thachil J, et al. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open. 2017;7(9):e017046.

55. Iba T, Levy JH, Connors JM, et al. The unique characteristics of COVID-19 coagulopathy. Crit Care. 2020;24(1):360.

56. Jardine L, Ingram G. Red cell fragmentation: D-dimer positive microangiopathic haemolytic anaemia. Br J Haematol. 2017;177(2):177.

57. Jilma-Stohlawetz P, Quehenberger P, Schima H, et al. Acquired von Willebrand factor deficiency caused by LVAD is ADAMTS-13 and platelet dependent. Thromb Res. 2016;137:196-201.

58. Kario K, Matsuo T, Nakao K. Serum erythropoietin levels in the elderly. Gerontology. 1991;37(6):345-348.

59. Kaushansky K, Lichtman MA, Prchal JT, et al. Williams hematology. 9th ed. New York: McGraw Hill Education; 2016.

60. Kedar PS, Colah RB, Ghosh K, et al. Experience with ektacytometry in evaluating red cell membrane disorders. Indian J Med Res. 2018;148(6):731-738.

61. Kemna EH, Tjalsma H, Willems HL, et al. Hepcidin: from discovery to differential diagnosis. Haematologica. 2008;93(1):90-97.

62. Kilickap S, Yavuz B, Aksoy S, et al. Addition of gemcitabine to paclitaxel-carboplatin combination increases survival in advanced non-small-cell lung cancer: a prospective phase II study. Cancer Chemother Pharmacol. 2008;62(6):1055-1060.

63. Kitchens CS, Konkle BA, Kessler CM. Consultative hemostasis and thrombosis. 3rd ed. Philadelphia, PA: Elsevier Saunders; 2013.

64. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-147.

65. Kratz A, Stanganelli C, van Leeuwen AM. Laboratory reference values. N Engl J Med. 2004;351(15):1548-1563.

66. Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology (Williston Park). 2015;29(4):282-294.

67. Lataillade JJ, Boval B, Drouet L. Scoring system for disseminated intravascular coagulation in critically ill patients: advantages of the International Society on Thrombosis and Haemostasis Scoring System. Crit Care Med. 2015;43(5):1100-1101.

68. Lesesve JF, Salignac S, Lecompte T. Laboratory measurement of schistocytes. Int J Lab Hematol. 2007;29(2):149-151.

69. Levi M, Scully M. How I treat disseminated intravascular coagulation. Blood. 2018;131(8):845-854.

70. Lewis RE, Cahyame-Zuniga L, Leventakos K, et al. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses. 2013;56(6):638-645.

71. Lippi G, Plebani M. Opportunistic screening for inherited thrombophilia might be considered in patients with unprovoked venous thromboembolism who are younger than 50 years or have family history. Semin Thromb Hemost. 2019;45(1):36-42.

72. Lippi G, Sanchis-Gomar F, Favaloro EJ, et al. Coronavirus disease 2019-associated coagulopathy. Mayo Clin Proc. 2021;96(1):203-217.

73. Makroo RN, Bhatia A, Chowdhry M, et al. Diagnostic performance of immature platelet fraction (IPF) as a marker of platelet recovery in thrombocytopenic patients. Pathol Lab Med Int. 2015;7:1-7.

74. Mancuso ME, Santagostino E. Platelets: much more than bricks in a breached wall. Br J Haematol. 2017;178(2):209-219.

75. Marini JJ, Dries DJ. Critical care medicine: the essentials. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013.

76. Mayank P, Sharma M, Das A, et al. Automated digital morphometry of peripheral blood smears for diagnosis of malarial infection. J Pathol Inform. 2020;11:4.

77. Mesaros C, Arora K, Chapman K, et al. Digital microscopy image analysis for objective peripheral blood smear evaluation: a promising approach. Int J Lab Hematol. 2019;41(5):671-683.

78. Moussavi-Harami SF, Mladinich KM, Sackmann EK, et al. Microfluidic device for concurrent analysis of neutrophil extracellular trap formation and cell migration. Biomicrofluidics. 2016;10(5):054124.

79. Muhaj FF, Harti H, El Abbassi I, et al. Thrombotic thrombocytopenic purpura in an intensive care unit: a series of 12 cases. Transfus Apher Sci. 2017;56(2):147-151.

80. Müller MC, Meijers JC, Vroom MB, et al. Utility of thromboelastography and/or thromboelastometry in adults with sepsis: a systematic review. Crit Care. 2014;18(1):R30.

81. Murthy JM, Sundaram C, Meena AK, et al. The influence of critically ill state on coagulation-related parameters: a prospective study. Neurol India. 2004;52(3):370-375.

82. Nahirniak S, Slichter SJ, Tanael S, et al. Guidance on platelet transfusion for patients with hypoproliferative thrombocytopenia. Transfus Med Rev. 2015;29(1):3-13.

83. Nakaishi H, Sanada M, Matsui H, et al. Nucleated red blood cells contribute to the risk of thrombotic events in patients with infectious disease. Int J Lab Hematol. 2015;37(4):e83-e86.

84. Naranje KM, Sonker A, Yadav D, et al. Utility of the blood smear examination in the assessment of anemia in children. Hematology. 2019;24(1):476-480.

85. Palmer L, Briggs C, McFadden S, et al. ICSH recommendations for the standardization of nomenclature and grading of peripheral blood cell morphological features. Int J Lab Hematol. 2015;37(3):287-303.

86. Patel U, Aronow WS, Patel R, et al. Dyslipidemia with acute pancreatitis—a case report and review of the literature. Arch Med Sci. 2015;11(5):1123-1126.

87. Paulus JM. Platelet size in man. Blood. 1975;46(3):321-336.

88. Pekelharing JM, Hauss O, de Jonge R, et al. Haematology reference intervals for established and novel parameters in healthy adults. Diagn Perspect. 2010;1:1-11.

89. Pepper DJ, Sun J, Welsh J, et al. Increased body mass index and adjusted mortality in ICU patients with sepsis or septic shock: a systematic review and meta-analysis. Crit Care. 2016;20(1):181.

90. Piek J, Lumbantoruan C, Latief IS, et al. Peripheral blood smear findings in COVID-19 patients: a systematic review. Postgrad Med J. 2022;98(1157):170-176.

91. Pierre RV. Red cell morphology and the peripheral blood film. Clin Lab Med. 2002;22(1):25-61.

92. Pimkin M, Sanz J, Wang Z, et al. Peripheral blood smear – a transformative tool for the early detection of sepsis. Crit Care Med. 2020;48(1):123-131.

93. Retter A, Sharp D, Gardiner D, et al. Sepsis leads to a dysregulated coagulation system in severe COVID-19. Intensive Care Med. 2021;47(4):465-476.

94. Romero PV, Román A, Roca J, et al. Extracorporeal lung support. Curr Opin Crit Care. 2010;16(1):53-58.

95. Sandhya I, Muddaiah A. Morphological changes in peripheral blood smear in tuberculosis patients before and after anti-tuberculosis treatment: a prospective observational study. Res Adv Hematol. 2020;5(1):10-15.

96. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059-1066.

97. Seferian A, Steriade A, Herasevich V, et al. Early prediction of intensive care unit admission for patients with moderate to severe coronavirus disease 2019 pneumonia. Crit Care Med. 2021;49(5):e470-e479.

98. Sharma P, Bhargava M, Sukhachev D, et al. LeukoFlow: multiparameter extended white blood cell differentiation for routine analysis by flow cytometry. Cytometry A. 2016;89(11):1076-1087.

99. Shi L, Wang Y, Wang Y, et al. Meta-analysis of relation of neutrophil-to-lymphocyte ratio with survival outcomes in patients with multiple myeloma. Front Oncol. 2021;11:645027.

100. Streiff MB, Agnelli G, Connors JM, et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis. 2016;41(1):32-67.

101. Tatsumi N, Pierre RV. Automated image processing: past, present, and future of blood cell morphology identification. Clin Lab Med. 2002;22(1):299-316.

102. Thachil J, Lisman T. Disseminated intravascular coagulation in COVID-19: implications for acutely ill patients. J Thromb Haemost. 2020;18(8):2118-2120.

103. Thachil J, Newland A, Harvey M, et al. Management of thrombocytopenia in critically ill patients. Br J Haematol. 2021;193(2):259-270.

104. Thomas L, Noel-Weidner J, Sontag TJ, et al. Comprehensive quality management in the medical laboratory. 1st ed. Berlin: De Gruyter; 2022.

105. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.

106. Vincent JL, De Backer D. Circulatory shock. N Engl J Med. 2013;369(18):1726-1734.

107. Vizioli L, Muscari S, Muscari A. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract. 2009;63(10):1509-1515.

108. Vogelzang M, Eijsbroek FJ, Nijsten MW, et al. Hyperoxia and outcome of critical illness: moving from confusion towards distinction. Crit Care. 2017;21(1):295.

109. Von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res. 2007;100(1):27-40.

110. Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. J Intensive Care. 2014;2(1):15.

111. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069.

112. Warkentin TE, Kaatz S. COVID-19 versus HIT hypercoagulability. Thromb Res. 2020;196:38-51.

113. Webert KE, Mittal R, Sigouin C, et al. A retrospective 11-year analysis of obstetric patients with idiopathic thrombocytopenic purpura. Blood. 2003;102(13):4306-4311.

114. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med. 1999;340(3):207-214.

115. Wilkinson JD, Pollack MM, Glass NL, et al. Mortality associated with multiple organ system failure and sepsis in pediatric intensive care unit. J Pediatr. 1987;111(3):324-328.

116. Xu JL, Qu XM, Zhang LG, et al. Early detection of cerebral infarction due to middle cerebral artery stenosis or occlusion: a study of 32 cases using diffusion-weighted magnetic resonance imaging. Neural Regen Res. 2016;11(6):979-987.

117. Yilmaz M, Cengiz M, Sanli ME, et al. Significance of immature granulocytes and delta neutrophil index for the diagnosis of acute appendicitis. Ulus Travma Acil Cerrahi Derg. 2018;24(4):351-356.

118. Yoon SH, Lee KH, Kim JY, et al. Chest radiographic and CT findings of the 2019 novel coronavirus disease (COVID-19): analysis of nine patients treated in Korea. Korean J Radiol. 2020;21(4):494-500.

119. Zachariah M, Patel B, Patel V, et al. Epidemiology, clinical features and outcome of candidemia in critically ill patients in a tertiary care ICU: a retrospective study. Crit Care Med. 2020;48(1):143.

120. Zandecki M, Genevieve F, Gerard J, et al. Spurious counts and spurious results on haematology analysers: a review. Part I: platelets. Int J Lab Hematol. 2007;29(1):4-20.